These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28324909)

  • 1. An Extrapericardial Minimally Invasive Approach for Implantable Cardioverter Defibrillator.
    Madjarov JM; Katz MG; Poole B; Madzharov S; Fedor JM; Robicsek F
    Thorac Cardiovasc Surg; 2017 Sep; 65(6):475-478. PubMed ID: 28324909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in the subcutaneous ICD.
    Willcox ME; Prutkin JM; Bardy GH
    Trends Cardiovasc Med; 2016 Aug; 26(6):526-35. PubMed ID: 27079889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abdominal submuscular implant of subcutaneous implantable cardioverter-defibrillator in a young child.
    Kwok SY; Yam N; Lun KS; Chen RH; Au TW; Yung TC
    Europace; 2018 Sep; 20(FI2):f248. PubMed ID: 29401320
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing.
    Payne JE; Badertscher P; Field ME; Sturdivant JL; Gold MR
    Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008631. PubMed ID: 32703008
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre comparison Of shock efficacy using single-vs. Dual-coil lead systems and Anodal vs. cathodaL polarITY defibrillation in patients undergoing transvenous cardioverter-defibrillator implantation. The MODALITY study.
    Baccillieri MS; Gasparini G; Benacchio L; Zorzi A; Marras E; Zerbo F; Tomasi L; Vaccari D; Pastore G; Bonanno C; Molon G; Zanotto G; Fusco A; Carasi M; Zorzi A; Calzolari V; Ignatiuk B; Cannas S; Vaglio A; Al Bunni M; Pedrini A; Olivieri A; Rampazzo R; Minicuci N; Corrado D; Verlato R
    J Interv Card Electrophysiol; 2015 Jun; 43(1):45-54. PubMed ID: 25690336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally invasive epicardial implantable cardioverter-defibrillator placement for infants and children: An effective alternative to the transvenous approach.
    Schneider AE; Burkhart HM; Ackerman MJ; Dearani JA; Wackel P; Cannon BC
    Heart Rhythm; 2016 Sep; 13(9):1905-12. PubMed ID: 27321244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iatrogenic Palpitations during Exercise in a Patient with a Dual Chamber Implantable Cardioverter-Defibrillator and Lead Dysfunction.
    Hasegawa K; Miyazaki S; Kaseno K; Tada H
    Int Heart J; 2019 Mar; 60(2):462-465. PubMed ID: 30626767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial experience with the use of cardioverter-defibrillator leads with DF-4 connector in the resynchronisation therapy].
    Maciąg A; Sterliński M; Zając D; Szwed H
    Kardiol Pol; 2013; 71(6):665-6. PubMed ID: 23797455
    [No Abstract]   [Full Text] [Related]  

  • 11. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approach to implantable cardioverter-defibrillators in small pediatric patients: dorsal positioning of superior vena cava shock lead in a 3-year-old.
    Pedersen SB; Smerup MH; Nielsen JC
    J Thorac Cardiovasc Surg; 2014 Jul; 148(1):358-60. PubMed ID: 24685380
    [No Abstract]   [Full Text] [Related]  

  • 13. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(2):1-5. PubMed ID: 21638938
    [No Abstract]   [Full Text] [Related]  

  • 14. Ventricular fibrillation undersensing due to air entrapment in a patient implanted with a subcutaneous cardioverter defibrillator.
    Adduci C; Spadoni L; Palano F; Francia P
    J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1373-1374. PubMed ID: 31165543
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C; Atienza F; Strasberg B; Arenal Á; Codner P; González-Torrecilla E; Datino T; Percal T; Almendral J; Ortiz M; Martins R; Martinez-Alzamora N; Fernandez Aviles F
    Cardiol J; 2015; 22(3):253-9. PubMed ID: 25179316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transvenous ICD implantation after artificial tricuspid valve replacement. A new approach placing a transvenous ICD lead in the mid cardiac vein of the coronary sinus.
    Gradaus R; Eckardt L; Wedekind H; Löher A; Böcker D
    Z Kardiol; 2005 Sep; 94(9):588-91. PubMed ID: 16142519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anesthesia care for subcutaneous implantable cardioverter/defibrillator placement: a single-center experience.
    Essandoh MK; Portillo JG; Weiss R; Otey AJ; Zuleta-Alarcon AN; Humeidan ML; Torres JL; Flores AS; Castellon-Larios K; Abdel-Rasoul M; Andritsos MJ; Perez WJ; Stein EJ; Turner KR; Dimitrova GT; Awad H; Bhandary SP; Tripathi RS; Joseph NC; Hummel JD; Augostini RS; Kalbfleisch SJ; Tyler JD; Houmsse M; Daoud EG
    J Clin Anesth; 2016 Jun; 31():53-9. PubMed ID: 27185678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients.
    Robin J; Weinberg K; Tiongson J; Carnethon M; Reddy M; Ciaccio C; Quadrini M; Hsu J; Fan J; Choi P; Kadish A; Goldberger J; Passman R
    Heart Rhythm; 2006 Oct; 3(10):1196-201. PubMed ID: 17018351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Submuscular Approach for Subcutaneous Implantable Cardioverter Defibrillator: A Potential Alternative Technique.
    Migliore F; Bottio T; Iliceto S; Bertaglia E
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):905. PubMed ID: 25704375
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.